EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL.

ABSTRACT:

Background

Hepatocellular Carcinoma (HCC) is a matter of great global public health importance; however, its current therapeutic effectiveness is deemed inadequate, and the range of therapeutic targets is limited. The aim of this study was to identify early growth response 1 (EGR1) as a transcription factor target in HCC and to explore its role and assess the potential of gene therapy utilizing EGR1 for the management of HCC.

Methods

In this study, both in vitro and in vivo assays were employed to examine the impact of EGR1 on the growth of HCC. The mouse HCC model and human organoid assay were utilized to assess the potential of EGR1 as a gene therapy for HCC. Additionally, the molecular mechanism underlying the regulation of gene expression and the suppression of HCC growt

SUBMITTER: Pan M 

PROVIDER: S-EPMC10823730 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature